Pfizer Inc.

NYSE:PFE

Drug Manufacturers - General

Healthcare
$28.06 -2.72%

-$0.71 today

Market cap
$159.94B
Beta
0.29
P/E (TTM)
19.2
EPS (TTM)
$1.32
Dividend yield
6.82%
52W Low $23.11High $28.75

Volume 37.37M

Average 36.66M

PFE Deferred Tax Liabilities

Taxes owed in future periods because of timing differences between accounting and tax rules.

Pfizer Inc.NYSE: PFE

Deferred Tax Liabilities · Q2 FY2026 · quarter ended Jun 2026

Deferred tax liabilities falls 20.8% from a year ago

Deferred tax liabilities stood at $1.96B at the end of Q2 FY2026, down 20.8% from a year earlier and down 18.6% from the prior quarter. Over 3 fiscal years it compounded at +32.9% a year.

Context

  • Deferred tax liabilities amounted to 1.0% of total assets at the end of Q2 FY2026, down 0.2 pp from a year earlier.
  • Deferred tax liabilities increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether deferred tax liabilities keeps falling in the next quarterly balance sheet after a -20.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.96B-18.6% QoQ
Last fiscal yearDec 2025
$2.4B+13.1% YoY
Year agoJun 2025
$2.48B-20.8% since
Deferred Tax Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.8%——
1 year+13.1%——
3-year CAGR+32.9%——
5-year CAGR——
10-year CAGR——

Deferred Tax Liabilities history

USD · from the balance sheet

Latest · FY2025
2.4B USD
Year-over-year change
+13.1%
4-year CAGR
+62.0%

Deferred Tax Liabilities vs competitors

How PFE compares with its peers on the latest reported figures

  • Peers report in different currencies, so deferred tax liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -20.8% is the 8th highest of 10, against a peer median of -10.1%.
  • Deferred tax liabilities amounts to 1.0% of total assets for PFE, versus a peer median of 1.4%.
PFE Competitors
Deferred Tax Liabilities for PFE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
LLYEli Lilly and CompanyJun 2026$5.46B USD——3.8%
NVSNovartis AGJun 2026$5.29B USD+128.0%+44.0%4.3%
JNJJohnson & JohnsonSep 2026$4.84B USD-19.3%+19.4%2.4%
AZNAstraZeneca PLCSep 2026$3.61B USD+0.2%+6.0%3.0%
ABBVAbbVie Inc.Jun 2026$2.28B USD-10.8%-2.9%1.7%
PFEPfizer Inc.Jun 2026$1.96B USD-20.8%+32.9%1.0%
SNYSanofiJun 2026€1.55B EUR-9.4%-3.3%1.2%
MRKMerck & Co., Inc.Jun 2026$1.43B USD+0.4%-7.1%1.1%
GILDGilead Sciences, Inc.Jun 2026$333M USD-48.9%-46.8%0.7%
GSKGSK plcJun 2026£301.17M GBP-42.8%+0.2%0.5%
BMYBristol-Myers Squibb CompanyJun 2026$222M USD-10.1%-53.2%0.3%
Peer median (excluding PFE) —-10.1%-2.9%1.4%

Competitors are the stored peer set for PFE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents1.94B416M2.85B1.04B1.14B
Short-term Investments29.13B22.32B9.84B19.43B12.45B
Net Receivables15.75B14.53B15.54B14.78B15.84B
Inventory9.06B8.98B10.19B10.85B10.65B
Other Current Assets3.82B5.02B4.91B4.25B2.81B
Total Current Assets59.69B51.26B43.33B50.36B42.9B
Property, Plant & Equipment (Net)14.88B16.27B18.94B18.39B21.53B
Goodwill49.21B51.38B67.78B68.53B71.26B
Intangible Assets25.15B43.37B64.9B55.41B53.73B
Long-term Investments21.53B15.07B15.37B2.23B1.74B
Tax Assets3.34B6.69B3.71B8.66B9.7B
Other Non-current Assets7.68B13.16B12.47B9.82B7.3B
Total Non-current Assets121.78B145.94B183.17B163.04B165.26B
Total Assets181.48B197.21B226.5B213.4B208.16B
Account Payables5.58B6.81B6.71B5.63B5.24B
Short-term Debt2.24B2.93B10.35B6.95B3.48B
Tax Payables1.27B1.59B2.35B00
Deferred Revenue3.07B2.52B2.7B1.51B784M
Other Current Liabilities28.27B25.99B23.32B23.2B18.32B
Total Current Liabilities42.67B42.14B47.79B43B36.98B
Long-term Debt34.76B31.93B60.5B57.41B61.64B
Deferred Tax Liabilities349M1.02B640M2.12B2.4B
Deferred Revenue (Non-current)00000
Other Non-current Liabilities26.24B26.2B28.28B20.09B18.07B
Total Non-current Liabilities61.34B59.15B89.42B81.9B84.4B
Total Liabilities104.01B101.29B137.21B124.9B121.39B
Common Stock473M476M478M480M481M
Retained Earnings103.39B125.66B118.35B116.73B114.61B
Accumulated OCI(5.9B)(8.3B)(7.96B)(7.84B)(8.07B)
Other Stockholders Equity00000
Minority Interest262M256M274M294M299M
Total Equity77.46B95.92B89.29B88.5B86.78B
Total Debt37B34.86B70.85B66.99B67.42B
Net Debt35.05B34.44B67.99B65.95B66.27B

Pfizer Inc.

NYSE:PFE

Intrinsic Alpha fair value

Locked

Current Price

$28.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.